Literature DB >> 20463596

CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.

Jae Yeo Park1, Dong-Hoon Jin, Chang-Min Lee, Min Ja Jang, Sun Young Lee, Hyo Seon Shin, Yoon Hee Chung, Kyung Yong Kim, Sung Su Kim, Won Bok Lee, Yong Kyoo Shin, Wang Jae Lee, Yeong-Min Park, Daejin Kim.   

Abstract

The requirement for CD4 T cells in priming and maintaining cytotoxic T-lymphocyte responses presents a long-standing paradox in cellular immunology. In this study, we used sequential coadministration of a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii-peptide region is replaced with CD4 T-helper epitope, PADRE [Pan human leukocyte antigen-DR reactive epitope (Ii-PADRE)] or Bcl-xL with a DNA vaccine encoding Sig/E7/LAMP-1 to verify the role of CD4 T cells for the generation of effectors and memory E7-specific CD8 T-cell immune responses. Sequential vaccination, with Ii-PADRE+Sig/E7/LAMP-1 priming followed by Bcl-xL+Sig/E7/LAMP-1 boosting led to generation of E7-specific CD8 T cells, and was nearly equivalent in effect to coadministration with Ii-PADRE+Sig/E7/LAMP-1 or Bcl-xL+Sig/E7/LAMP-1 at both prime and boost. The mice vaccinated with the Ii-PADRE+Sig/E7/LAMP-1 prime-Bcl-xL+Sig/E7/LAMP-1 boost regimen exhibited better long-term E7-specific immune responses and tumor prevention effects in vivo than the mice vaccinated with the reverse sequential coadministration. After CD4 T-cell depletion, mice primed with Ii-PADRE+Sig/E7/LAMP-1 generated low numbers of E7-specific CD8 T cells and suppressed long-term memory CD8 T-cell response regardless of the sequence or combination of DNA vaccines administered. Mice primed with Bcl-xL+Sig/E7/LAMP-1 only suppressed long-term memory CD8 T-cell response after depletion of CD4 T cells before priming. Our findings suggest that activated CD4 T cells at prime phase are important to generate the antigen-specific CD8 T-cell immune responses and CD4 T cells, which are naive or activated, play a role to maintain the long-term memory responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463596     DOI: 10.1097/CJI.0b013e3181d75cef

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

1.  Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.

Authors:  Koji Teramoto; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka; Keiichi Kontani
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

2.  Chemokine-enhanced DNA vaccination in cancer immunotherapy.

Authors:  Olga Igoucheva; Rebecca Jonas; Vitali Alexeev
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

3.  Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.

Authors:  Filipe M de Melo; Catarina J M Braga; Felipe V Pereira; Juliana T Maricato; Clarice S T Origassa; Mariana F Souza; Amanda C Melo; Priscila Silva; Samanta L Tomaz; Karina P Gimenes; Jorge A B Scutti; Maria A Juliano; Dario S Zamboni; Niels O Câmara; Luiz R Travassos; Luis C S Ferreira; Elaine G Rodrigues
Journal:  Immunol Cell Biol       Date:  2014-09-16       Impact factor: 5.126

4.  Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity.

Authors:  Yunfei Zhang; Yong Zhang; Jun Chen; Yunyan Liu; Wen Luo
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

5.  Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

Authors:  Cindy Tamminga; Martha Sedegah; Santina Maiolatesi; Charlotte Fedders; Sharina Reyes; Anatalio Reyes; Carlos Vasquez; Yolanda Alcorta; Ilin Chuang; Michele Spring; Michael Kavanaugh; Harini Ganeshan; Jun Huang; Maria Belmonte; Esteban Abot; Arnel Belmonte; Joglenna Banania; Fouzia Farooq; Jittawadee Murphy; Jack Komisar; Nancy O Richie; Jason Bennett; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Meng Shi; Edward Miller; Sheetij Dutta; Carter Diggs; Lorraine A Soisson; Michael R Hollingdale; Judith E Epstein; Thomas L Richie
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.